ROARABLE // PRO
GLOBAL DESKS // NYC --:--:-- NYSE
US TAPE
ROAR ▸
COMP <GO>

CING vs COYA // GROSS PROFIT MARGIN

Cingulate Inc. (NASDAQ) VS. Coya Therapeutics Inc. (NASDAQ) • 15-METRIC TALLY: CING 1 — COYA 3
■ METRIC PARITY
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (CING VS. COYA) EMERALD CELL = QUANTITATIVE EDGE
INSTITUTIONAL METRIC CING COYA SPREAD (A - B) ADVANTAGE DEDICATED URL
Gross Profit Margin ACTIVE — — — TIE /gross-margins <GO>
Return on Invested Capital (ROIC) -35.00% -35.00% 0.00 TIE /roic <GO>
EV/EBITDA & P/E Valuation — — — TIE /valuation <GO>
Free Cash Flow Yield -23.06% -11.50% -11.56 COYA /fcf-yield <GO>
Operating Margin — -60.00% — TIE /operating-margins <GO>
Net Profit Margin — -60.00% — TIE /net-margins <GO>
Revenue Growth (YoY) — 123.60% — TIE /revenue-growth <GO>
Dividend Yield & FCF Payout Safety 0.00% 0.00% 0.00 TIE /dividend-safety <GO>
Altman Z-Score & Debt/Equity — 6.08 — TIE /balance-sheet <GO>
Piotroski F-Score Quality 2/9 3/9 -1.00 COYA /piotroski-score <GO>
Options Implied Move & Put/Call Skew — — — TIE /options-implied-move <GO>
RSI-14 & 200D SMA Momentum 53.1 22.0 +31.10 CING /rsi-technicals <GO>
10Y Yield & FRED Macro Beta — — — TIE /macro-sensitivity <GO>
Forward P/E Multiple — — — TIE /forward-pe <GO>
Enterprise Scale & Market Cap $73.1M $75.8M -$2.6M COYA /market-cap <GO>
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
FISCAL YEAR CING REV COYA REV CING GROSS % COYA GROSS % CING FCF COYA FCF
FY 2025 $55.8M $7.9M — — -$17.4M -$10.7M
FY 2024 $43.8M $3.6M — — -$18.7M -$10.3M
FY 2023 $63.7M $6.0M — — -$15.0M -$11.2M
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
CING // BETA —
COYA // BETA —